论文部分内容阅读
目的探讨匹维溴铵(得舒特)联合益生菌(培菲康,双歧杆菌三联活菌胶囊)在腹泻型肠易激综合征(D-IBS)临床治疗中的效果,为今后的用药方案提供参考。方法 80例D-IBS患者,采用平行随机抽样法将其分为对照组与观察组,各40例,对照组给予口服思密达治疗,观察组给予得舒特联合益生菌治疗,治疗后对比两组的症状总积分与临床疗效。结果治疗后,观察组的症状总积分为(6.71±1.82)分明显低于对照组的症状总积分(9.31±1.75)分,差异具有统计学意义(P<0.05)。观察组中,治愈11例,显效19例,有效7例,无效3例。对照组中,治愈4例,显效9例,有效14例,无效13例。观察组总有效率为92.5%(37/40)明显高于对照组总有效率67.5%(27/40),差异具有统计学意义(P<0.05)。结论得舒特联合益生菌治疗D-IBS,可以有效改善腹痛、腹泻等临床症状,提高治疗效果,可以作为D-IBS治疗的首选用药方案在临床推广应用。
Objective To investigate the effect of pivtimurium combined with probiotics (Bifidobacterium and Bifidobacterium triple viable capsule) in the clinical treatment of diarrhea-predominant irritable bowel syndrome (D-IBS) for future treatment Program for reference. Methods 80 cases of D-IBS patients were divided into control group and observation group by parallel random sampling method, 40 cases in each group. The control group was treated with oral metmin, the observation group was treated with dextrose combined with probiotics. After treatment, The total score of the two groups and clinical efficacy. Results After treatment, the total score of symptoms in the observation group was (6.71 ± 1.82) points lower than that in the control group (9.31 ± 1.75) points, the difference was statistically significant (P <0.05). In the observation group, 11 cases were cured, 19 cases markedly effective, 7 effective and 3 ineffective. In the control group, 4 cases were cured, 9 cases markedly effective, 14 cases effective, and 13 cases ineffective. The total effective rate in the observation group was 92.5% (37/40), which was significantly higher than that in the control group (67.5%, 27/40). The difference was statistically significant (P <0.05). Conclusion D-shuet combined probiotics treatment of D-IBS, can effectively improve the clinical symptoms such as abdominal pain, diarrhea and improve the therapeutic effect, which can be used as D-IBS treatment in the clinical application of the program.